| 摘要 |
The rate of viral resistance developed during the course of treatment with antiviral nucleoside analogues is reduced by administering dsRNAs early in the treatment of the infection or in later stages when viral genetic mutation has occured to restore susceptibility of the virus to otherwise ineffective antiviral agents. Delaying and/or reducing the appearance of nucleoside analogue resistant retroviruses, particularly HIV, is achieved with mismatched dsRNAs notably in the peripheral blood mononuclear cells, especially the CD4 lymphocytes. |
